Professor Robert Hills
Contact information
Research groups
- A comparison of individual patient data (IPD) over meta-analyses of published data, implications for clinical trial design and the utility of endpoints for early breast cancer trials. CRUK STUDENTSHIP AVAILABLE
- Assessing benefits and harms in early breast cancer: predictive and prognostic factors in early breast cancer and long-term side-effects of therapy. CRUK STUDENTSHIP AVAILABLE
Robert Hills
Professor of Medical Statistics
Robert Hills studied mathematics at the University of Oxford, where his DPhil was on exploration of symmetries with applications to superconductivity. He joined the CTSU in 1993 as a programmer on the QUASAR trial in colorectal cancer. Following a brief period working in low temperature physics at the University of Nottingham, he moved to the University of Birmingham Clinical Trials Unit (BCTU) in 1997.There, he worked on clinical trials in Acute Myeloid Leukaemia, Alzheimer’s Disease, women’s health and many others as well as large scale individual patient data meta-analyses of treatment for colorectal cancer.
In 2006, he moved to Cardiff University as statistical lead for the NCRI/MRC trials in Acute Myeloid Leukaemia. During his 12 years in Cardiff he was head of the Haematology Clinical Trials Unit, and latterly led on clinical cancer research methodology and haematological malignancies. The novel designs used in these trials allow the clinical value of disease monitoring to be evaluated, as well as numerous targeted therapies in designs that allow for an early change from an unpromising new therapy to one with greater potential. Additionally, he continued his work on the integration of laboratory and clinical data, and on individual patient data meta-analyses, where he demonstrated a survival benefit for gentuzumab ozogamicin in AML.
In 2018, he moved back to the University of Oxford where he is part of the Early Breast Cancer Trialists' Collaborative Group.
Recent publications
-
Anthracycline and taxane containing chemotherapy for early-stage operable breast cancer: meta-analyses of 100,000 women in 86 randomised trials
Journal article
Taylor CAROLYN. et al, (2023), The Lancet
-
Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG.
Journal article
Othus M. et al, (2022), Leuk Lymphoma, 1 - 3
-
Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type Diffuse Large B Cell Lymphoma.
Journal article
Bewicke-Copley F. et al, (2022), Blood Adv
-
A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial.
Journal article
Russell NH. et al, (2022), Br J Haematol, 198, 528 - 534
-
Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial.
Journal article
Russell NH. et al, (2022), Haematologica, 107, 1518 - 1527